Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (19751)	3/14/1999 3:39:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

DaiS: <<I note that you show more enthusiasm for the Berman study rather than the Kaplan study which got past the Urology referees. I hope it is not because you know something disreputable about Dr Kaplan.>> DaiS: Dr. Kaplan is a prominent well-respected NYC urologist. As he has noted, his study has limitations including the absence of a placebo control, absence of entry criteria, the small study size, and the difficulty in subjectively measuring efficacy for FSD. www3.techstocks.com The Berman/Goldstein study was a placebo-controlled , double-blind crossover study that also made use of duplex doppler ultasonagraphy to measure sexual response. The study's main drawback is its small study size of 17 women. It should also be noted that both studies were conducted with funding outside of the pharmaceutical industry. BigKNY3